CAPS抗体;CAPS Antibody—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human pancreas tissue and Human kidney tissue lysates, Primary antibody: P13008(CAPS Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 90 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P13008(CAPS Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

CAPS antibodies, also called anti-caps antibodies, target the capsular polysaccharides (CAPS) of encapsulated bacteria like *Streptococcus pneumoniae* and *Haemophilus influenzae*. These antibodies play a critical role in adaptive immunity by binding to bacterial surface polysaccharides, promoting opsonization, phagocytosis, and complement-mediated clearance.

CAPS antibodies are primarily IgG, though IgM and IgA subtypes also contribute. Their production is T-cell-independent, relying on B-cell recognition of repetitive polysaccharide structures. This mechanism underpins the effectiveness of polysaccharide-based vaccines (e.g., pneumococcal vaccines), which stimulate long-term immune memory against specific serotypes.

Clinically, measuring CAPS antibody levels is vital for assessing immune competence, particularly in patients with recurrent infections or immunodeficiencies (e.g., common variable immunodeficiency). Low antibody titers post-vaccination may indicate impaired humoral immunity. However, CAPS antibody responses vary by age; young children and the elderly often exhibit weaker responses due to immune system immaturity or senescence.

Research continues to optimize CAPS-targeted vaccines and therapies, especially for high-risk populations. Understanding these antibodies also informs diagnostic strategies for bacterial infections and guides immunoglobulin replacement therapies in immunocompromised individuals.